Endothelial barrier dysfunction in septic shock

Journal of Internal Medicine

Volumn 277, Issue 3, 2015, Pages 277-293

  Opal, S M ^a   van der Poll, T ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Endothelial barrier; Endothelial junctions; Protease activated receptors; Sepsis; Sepsis induced immunosuppression; Septic shock

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; COMPLEMENT COMPONENT C5A; FIBRINOPEPTIDE B; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN ROBO4; PROTEINASE ACTIVATED RECEPTOR; ROUNDABOUT RECEPTOR; SLIT PROTEIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; FIBRIN DEGRADATION PRODUCT; FIBRINOPEPTIDE BBETA (15-42); HMGB1 PROTEIN, HUMAN; LYSOPHOSPHOLIPID; NERVE PROTEIN; PEPTIDE FRAGMENT; ROBO4 PROTEIN, HUMAN; SIGNAL PEPTIDE; SLIT HOMOLOG 2 PROTEIN; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; VASCULOTROPIN A;

ADVERSE OUTCOME; BLOOD CLOTTING; CELL INTERACTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; ANALOGS AND DERIVATIVES; CELL COMMUNICATION; HOMEOSTASIS; MEMBRANE MICROPARTICLE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOPOIETIN-1; BIOLOGICAL MARKERS; CELL COMMUNICATION; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HMGB1 PROTEIN; HOMEOSTASIS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICROCIRCULATION; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; RECEPTORS, PROTEINASE-ACTIVATED; SHOCK, SEPTIC; SPHINGOSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923014522     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12331     Document Type: Review

References (140)

1. McEvoy C, Kollef MH. Determinants of hospital mortality among patients with sepsis or septic shock receiving appropriate antibiotic treatment. Curr Infect Dis Rep 2013; 15: 400-6.
2. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-51.
3. Bosmann M, Ward PA. The inflammatory response in sepsis. Trends Immunol 2013; 34: 129-36.
4. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet 2013; 381: 774-5.
5. Dellinger RP, Levy MM, Rhodes A et al. The surviving sepsis guidelines: 2012. Crit Care Med 2013; 41: 580-637.
6. Opal SM, Dellinger RP, Vincent J-L, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med 2014; 42: 1714-21.
7. Deutchman CS, Tracey KJ. Sepsis: current dogma and new perspectives. Immunity 2014; 40: 463-75.
8. Hotchkiss RS, Opal SM. Immunotherapy for sepsis: a new approach against an ancient foe. N Engl J Med 2010; 363: 87-9.
9. Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011; 306: 2614-5.
10. Ranieri VM, Thompson BT, Barie PS et al. Drotrecogin alfa (activated) for adults with septic shock. N Engl J Med 2012; 366: 2055-64.
11. Kaukonen K-M, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand. JAMA 2014; 331: 1308-16.
12. Galbois A, Aegerter P, Martel-Samb P et al. Improved prognosis of septic shock in patients with cirrhosis: a multicenter study. Crit Care Med 2014; 42: 1666-75.
13. Yealy DM, Kellum JA, Huang DT et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370: 1683-93.
14. Andersson U, Tracey KJ. Neural reflexes in inflammation and immunity. J Exp Med 2012; 209: 1057-68.
15. Brealey D, Brand M, Hargreaves I et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360: 219-23.
16. Haneklaus M, O'Neill LA, Coli RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013; 25: 40-5.
17. Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev 2013; 93: 1247-88.
18. McGettrick AF, O'Neill LA. How metabolism generates signals during innate immunity and inflammation. J Biol Chem 2013; 288: 22893-8.
19. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012; 335: 936-41.
20. Ward PA, Bosmann M. A historical perspective on sepsis. Am J Pathol 2012; 181: 2-7.
21. Nakahira K, Haspel JA, Rathinam VAK et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011; 12: 222-30.
22. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140: 871-82.
23. Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 2014; 5: 66-72.
24. Xiao W, Mindrinros MN, Seok J et al. A genomic storm in critical injured humans. J Exp Med 2011; 208: 2581-90.
25. Chavan SS, Huerta PT, Robbiati S et al. HMGB1 mediates cognitive impairment in sepsis survivors. Mol Med 2012; 18: 930-7.
26. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-62.
27. Angus DC. The lingering consequences of sepsis: the Hidden public health disaster? JAMA 2010; 304: 1833-4.
28. Boomer JS, To K, Chang KC et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306: 2594-605.
29. Felmet KA, Hall MW, Clark RSB, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005; 174: 3765-72.
30. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010; 327: 296-300.
31. Borovikova LV, Ivanova S, Zhang M et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.
32. Chiu IMI, Heesters BA, Ghasemlou N et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature 2013; 501: 52-7.
33. Rosas-Ballina M, Ochani M, Parrish WR et al. Splenic nerve is required for cholinergic anti-inflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci USA 2008; 105: 11008-13.
34. Casaer MP, van den Berghe G. Nutrition in the acute phase of critical illness. N Engl J Med 2014; 78: 1227-35.
35. Levy RJ, Deutschman CS. Cytochrome c oxidase dysfunction in sepsis. Crit Care Med Suppl 2007; 35: S468-75.
36. Horng T. Calcium signaling and mitochondrial destabilization in the triggering of the NLRP3 inflammasome. Trends Immunol 2014; 35: 253-61.
37. Walton AH, Muenzer JT, Rasche D et al. Reactivation of multiple viruses in patients with sepsis. PLoS ONE 2014; 9: e98819.
38. Cavaillon J-M, Eisen D, Annane D. Is boosting the immune system in sepsis appropriate? Crit Care 2014; 18: 216.
39. Jani IV, Peter TF. How point-of-care testing could drive innovation in global health. N Engl J Med 2013; 368: 2319-24.
40. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med 2010; 363: 689-91.
41. London NR, Zhu W, Bozza FA et al. Targeting Robo4-dependent Slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2010; 2: 23ra19.
42. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003; 101: 3765-77.
43. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536-45.
44. Levi M, van der Poll T. Endothelial injury in sepsis. Intensive Care Med 2013; 39: 1839-42.
45. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38(2 Suppl): S26-34.
46. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-6.
47. Carr C, Bild GS, Chang AC et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 126-37.
48. Pawlinski R, Pedersen B, Schabbauer G et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004; 103: 1342-7.
49. Meziani F, Delabranche X, Asfar P, Toti F. Bench-to-bedside review: circulating microparticles-a new player in sepsis? Crit Care 2010; 14: 236.
50. Szotowski B, Antoniak S, Rauch U. Alternatively spliced tissue factor: a previously unknown piece in the puzzle of hemostasis. Trends Cardiovasc Med 2006; 16: 177-82.
51. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking. J Thromb Haemost 2007; 5: 1097-105.
52. Ott I, Miyagi Y, Miyazaki K et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874-82.
53. Sandset PM, Warn-Cramer BJ, Maki SL, Rapaport SI. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized Shwartzman reaction. Blood 1991; 78: 1496-502.
54. Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88: 708-12.
55. de Jonge E, Dekkers PE, Creasey AA et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-9.
56. Danese S, Vetrano S, Zhang L, Poplis VA, Castellino FJ. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115: 1121-30.
57. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
58. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-6.
59. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
60. Bockmeyer CL, Claus RA, Budde U et al. Inflammation-associated ADAMTS13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 2008; 93: 137-40.
61. Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86: 743-51.
62. de Stoppelaar SF, van 't Veer C, van der Poll T. The role of platelets in sepsis. Thromb Haemost 2014; 26: 112(2).
63. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
64. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002; 106: 2111-7.
65. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10: 171-8.
66. Gardiner EE, Andrews RK. Neutrophil extracellular traps (NETs) and infection-related vascular dysfunction. Blood Rev 2012; 26: 255-9.
67. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012; 189: 2689-95.
68. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014; 123: 2768-76.
69. Saffarzadeh M, Juenemann C, Queisser MA et al. Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS ONE 2012; 7: e32366.
70. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 2001; 98: 7742-7.
71. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
72. Kaneider NC, Leger AJ, Agarwal A et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007; 8: 1303-12.
73. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci U S A 2002; 99: 643-8.
74. Wielders SJ, Bennaghmouch A, Reutelingsperger CP, Bevers EM, Lindhout T. Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists. J Thromb Haemos 2007; 5: 571-6.
75. Tressel SL, Kaneider NC, Kasuda S et al. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011; 3: 370-84.
76. Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood 2013; 121: 431-9.
77. Austin KM, Nguyen N, Javid G, Covic L, Kuliopulos A. Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis. J Biol Chem 2013; 288: 23105-15.
78. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-32.
79. Cohen I, Rider P, Carmi Y et al. Differential release of chromatin-bound IL-1 alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA 2010; 107: 2574-9.
80. Eigenbrod T, Park JH, Harder J, Iwakura Y, Nunez G. Cutting edge: critical role of mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol 2008; 181: 8194-8.
81. Baer C, Squadrito ML, Iruela-Arispe ML, DePalma M. Reciprocal interactions between endothelial cells and macrophages in angiogenic vascular niches. Expert Cell Res 2013; 319: 1626-34.
82. Parikh SM, Mammoto T, Schultz H et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: e46.
83. Huges DP, Marron MB, Brindle NP. The anti-inflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-Kappa B inhibitor ABIN-2. Cir Res 2003; 92: 630-6.
84. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-79.
85. Simons M, Raposo G. Exosomes-vesicular carriers of intercellular communication. Curr Opin Cell Biol 2009; 21: 575-81.
86. Zhang Y, Liu D, Chen X et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39: 133-44.
87. He H, Xu J, Carmen M et al. Endothelial cells provide an instructive niche for the differentiation and functional polarization of M2-like macrophages. Blood 2012; 120: 3152-62.
88. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-51.
89. Norling LV, Dalli J. Microparticles are novel effectors of immunity. Curr Opin Pharmacol 2013; 13: 570-5.
90. Berckmans RJ, Nieuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-46.
91. Jy W, Jimenez JJ, Mauro LM et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 2005; 3: 1301-8.
92. Satta N, Toti F, Feugeas O et al. Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 1994; 153: 3245-55.
93. Delabranche X, Boisrame-Helms J, Asfar P et al. Microparticles are new biomarkers of septic shock-induced disseminated intravascular coagulopathy. Intensive Care Med 2013; 39: 1695-703.
94. Perez-Casal M, Downey C, Cutillas-Moreno B, Zuzel M, Fukudome K, Toh CH. Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects. Haematologica 2009; 94: 387-94.
95. Perez-Casal M, Thompson V, Downey C et al. The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care 2011; 15: R195.
96. Lundy DJ, Trzeciak S. Microcirculatory dysfunction in sepsis. Crit Care Nurs Clin North Am 2011; 23: 67-77.
97. De Backer D, Orbegozo Cortes D, Donadello K, Vincent JL. Pathophysiology of microcirculatory dysfunction and the pathogenesis of septic shock. Virulence 2014; 5: 73-9.
98. Edul VS, Enrico C, Laviolle B, Vazquez AR, Ince C, Dubin A. Quantitative assessment of the microcirculation in healthy volunteers and in patients with septic shock. Crit Care Med 2012; 40: 1443-8.
99. De Backer D, Donadello K, Sakr Y et al. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med 2013; 41: 791-9.
100. Piagnerelli M, Boudjeltia KZ, Vanhaeverbeek M, Vincent JL. Red blood cell rheology in sepsis. Intensive Care Med 2003; 29: 1052-61.
101. Gierer P, Hoffmann JN, Mahr F et al. Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia. Crit Care Med 2007; 35: 1966-71.
102. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med 2006; 34: 1918-24.
103. Hoffmann JN, Vollmar B, Romisch J, Inthorn D, Schildberg FW, Menger MD. Antithrombin effects on endotoxin-induced microcirculatory disorders are mediated mainly by its interaction with microvascular endothelium. Crit Care Med 2002; 30: 218-25.
104. Iba T, Okamoto K, Ohike T et al. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats. J Trauma Acute Care Surg 2012; 72: 177-82.
105. Goldenberg NM, Steinberg BE, Slutsky AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011; 22: 3 (88):88 ps25.
106. Darwish I, Liles WC. Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction. Virulence 2013; 4: 572-82.
107. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-71.
108. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8: 1223-34.
109. Wang L, Dudek SM. Regulation of vascular permeability by sphingosine 1-phosphate. Microvasc Res 2009; 77: 39-45.
110. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105: 3178-84.
111. Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37: 222-31.
112. Bae JS, Kim YU, Park MK, Rezaie AR. Concentration dependent dual effect of thrombin in endothelial cells via Par-1 and Pi3 Kinase. J Cell Physiol 2009; 219: 744-51.
113. Zhang G, Yang L, Kim GS et al. Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood 2013; 122: 443-55.
114. Petzelbauer P, Zacharowski PA, Miyazaki Y et al. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 2005; 11: 298-304.
115. Groger M, Pasteiner W, Ignatyev G et al. Peptide Bbeta(15-42) preserves endothelial barrier function in shock. PLoS ONE 2009; 4: e5391.
116. Roesner JP, Petzelbauer P, Koch A et al. Bbeta15-42 (FX06) reduces pulmonary, myocardial, liver, and small intestine damage in a pig model of hemorrhagic shock and reperfusion. Crit Care Med 2009; 37: 598-605.
117. Jennewein C, Mehring M, Tran N et al. The fibrinopeptide bbeta15-42 reduces inflammation in mice subjected to polymicrobial sepsis. Shock 2012; 38: 275-80.
118. Matt U, Warszawska JM, Bauer M et al. Bbeta(15-42) protects against acid-induced acute lung injury and secondary pseudomonas pneumonia in vivo. Am J Respir Crit Care Med 2009; 180: 1208-17.
119. Atar D, Petzelbauer P, Schwitter J et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009; 53: 720-9.
120. Jones CA, London NR, Chen H et al. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nat Med 2008; 14: 448-53.
121. Jones CA, Nishiya N, London NR et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol 2009; 11: 1325-31.
122. Zhu W, London NR, Gibson CC et al. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. Nature 2012; 492: 252-5.
123. Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence 2013; 4: 507-16.
124. Parikh SM, Mammoto T, Schultz A et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3: e46.
125. Kumpers P, Lukasz A, David S et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008; 12: R147.
126. David S, Mukherjee A, Ghosh CC et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med 2012; 40: 3034-41.
127. Kumpers P, Gueler F, David S et al. The synthetic tie2 agonist peptide vasculotide protects against vascular leakage and reduces mortality in murine abdominal sepsis. Crit Care 2011; 15: R261.
128. David S, Ghosh CC, Kumpers P et al. Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. Am J Physiol Lung Cell Mol Physiol 2011; 300: L851-62.
129. Alfieri A, Watson JJ, Kammerer RA et al. Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis. Crit Care 2012; 16: R182.
130. Lamkanfi M, Sarkar A, Walle LV et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 2010; 185: 4385-92.
131. Cisowski J, O'Callaghan K, Kuliopulos A et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 2011; 179: 513-23.
132. Sevigny LM, Zhang P, Bohm A et al. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci U S A 2011; 108: 8491-6.
133. Boucheix OB, Milano SP, Henriksson M, Reinheimer TM. Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs. Shock 2013; 39: 533-8.
134. Ward P. The harmful role of C5a on innate immunity in sepsis. J Innate Immun 2010; 2: 439-45.
135. Vincent J-L, Ramesh MK, Ernest D et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41: 2069-79.
136. Denk S, Perl M, Huber-Lang M. Damage and pathogen associated molecular patterns and alarmins: keys to sepsis? Eur Surg Res 2014; 48: 171-9.
137. Wolfson RK, Chiang ET, Garcia JGN. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res 2011; 81: 189-97.
138. Huang W, Liu Y, Li L et al. HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinases. Inflammation 2012; 35: 350-62.
139. Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-60.
140. Rao DA, Tracey KJ, Pober JS. IL-1alpha and IL-1beta are endogenous mediators linking cell injury to adaptive alloreactive responses. J Immunol 2007; 179: 6536-46.